Glenn Chertow, MD
Nephrology · Stanford, CANPI 1407823875
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $1,831,004 of the $2,021,578 with a category attached, or 90.6%. 26 manufacturers reported payments, led by Outset Medical Inc at 31.8% of the total. Among nephrology clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 355 payments — averaging $5694.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Outset Medical Inc$642K
- Akebia Therapeutics Inc$312K
- AstraZeneca$298K
- Vertex$252K
- Ardelyx, Inc.$194K
- Gilead$94K
- plus $230K from 20 others
Across 43 payments — averaging $7718.25 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$234K
- Bayer$70K
- Janssen Research & Development, LLC$27K
- Gilead$890
- Akebia Therapeutics Inc$420
What the payments were for
- Consulting fees$1,831,00491%
- Speaking & faculty fees$159,3778%
- Travel & lodging$26,9981%
- Food & beverage$4,1980%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Outset Medical Inc | 15 | $642,016 |
| Akebia Therapeutics Inc | 48 | $311,813 |
| AstraZeneca(2 entities) | 69 | $297,909 |
| Vertex | 56 | $252,204 |
| Ardelyx, Inc. | 27 | $193,732 |
| Gilead | 22 | $93,629 |
| Astrazeneca UK Limited | 33 | $75,204 |
| Astrazeneca AB | 10 | $40,475 |
| Bayer | 24 | $25,755 |
| Travere Therapeutics, Inc. | 6 | $20,028 |
| GSK | 5 | $18,067 |
| Baxter Healthcare | 9 | $14,484 |
| CSL Behring | 9 | $13,416 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 2 | $6,445 |
| Alnylam Pharmaceuticals Inc. | 2 | $5,860 |
| ZOLL Medical Corporation | 3 | $3,017 |
| Insmed, Inc. | 2 | $1,697 |
| Novo Nordisk AS | 1 | $1,575 |
| Kyowa Kirin Co., Ltd | 2 | $1,101 |
| Beigene USA, Inc. | 1 | $1,000 |
| Lilly USA, LLC | 1 | $825 |
| Amgen | 3 | $778 |
| Vifor (international) Ltd. | 1 | $317 |
| Novo Nordisk | 1 | $108 |
| Novartis | 2 | $65 |
| Aurinia Pharma U.S., Inc. | 1 | $58 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Vafseo$95,762
- FARXIGA$76,465
- XPHOZAH 30 MG$73,100
- AURYXIA$62,248
- Non-Covered$23,109
- LOKELMA$15,600
- Renal - Theranova$14,347
- Defibrillator$3,017
- Kerendia$2,002
- JARDIANCE$825
- Tavneos$732
- Ozempic$108
- ULTOMIRIS$100
How this compares
$2,021,578 in reported general payments places this provider in the 95th percentile of 1,341 nephrology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 209 | $201,721 |
| MounjaroTirzepatide | 43 | $44,968 |
| JardianceEmpagliflozin | 30 | $35,447 |
| OzempicSemaglutide | 27 | $25,295 |
| TrulicityDulaglutide | 21 | $24,625 |
| Sevelamer Carbonate | 37 | $18,957 |
| DapagliflozinDapagliflozin Propanediol | 23 | $15,802 |
| Calcium Acetate | 50 | $6,468 |
| Losartan Potassium | 71 | $883 |
| Chlorthalidone | 76 | $747 |
| Carvedilol | 56 | $728 |
| Valsartan | 27 | $651 |
| Mycophenolate Mofetil | 14 | $635 |
| Amlodipine Besylate | 86 | $424 |
| Spironolactone | 19 | $421 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga | $297,909 | $201,721209 claims |
| Lilly USA, LLCMounjaro, Trulicity | $825 | $69,59364 claims |
| Novo NordiskOzempic | $108 | $25,29527 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,341 nephrology providers in California.
Other nephrology in Stanford
- Richard LafayetteStanford$467K
- Vivek BhallaStanford$78K
- Anjay RastogiLos Angeles$2.2M
- Luis AlvarezPalo Alto$1.8M
- Jose MorfinSacramento$1M
- Rodolfo BatarseRancho Mirage$910K
- Vandana MathurWoodside$769K
- Yasir QaziOrange$618K
- Rafael VillicanaLoma Linda$610K
- Sunil PatelApple Valley$509K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.